Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F HOUSSIAU

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
The Journal of Rheumatology|January 27, 2000
Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLEM Galeazzi, P Annunziata, G D Sebastiani, et al.
Arthritis Care & Research|August 29, 2015
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension StudyD J Wallace, K Hobbs, M E B Clowse, et al.
Annals of the Rheumatic Diseases|April 25, 2008
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpointsG K Bertsias, J P A Ioannidis, J Boletis, et al.
Annals of the Rheumatic Diseases|May 17, 2007
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsG Bertsias, J P A Ioannidis, J Boletis, et al.
Annals of the Rheumatic Diseases|April 5, 2008
EULAR points to consider for conducting clinical trials in systemic lupus erythematosusC Gordon, G Bertsias, J P A Ioannidis, et al.
Lupus|February 14, 2009
European consensus statement on the terminology used in the management of lupus glomerulonephritisC Gordon, D Jayne, C Pusey, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Annals of the Rheumatic Diseases|September 20, 2008
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patientsR Cervera, M A Khamashta, Y Shoenfeld, et al.
Annals of the Rheumatic Diseases|January 28, 2014
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsR Cervera, R Serrano, G J Pons-Estel, et al.
Genes and Immunity|October 21, 2011
The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosisJ-E Martin, F D Carmona, J C A Broen, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Journal of Rheumatology|January 27, 2000
Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLEM Galeazzi, P Annunziata, G D Sebastiani, et al.
Arthritis Care & Research|August 29, 2015
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension StudyD J Wallace, K Hobbs, M E B Clowse, et al.
Annals of the Rheumatic Diseases|April 25, 2008
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpointsG K Bertsias, J P A Ioannidis, J Boletis, et al.
Annals of the Rheumatic Diseases|May 17, 2007
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsG Bertsias, J P A Ioannidis, J Boletis, et al.
Annals of the Rheumatic Diseases|April 5, 2008
EULAR points to consider for conducting clinical trials in systemic lupus erythematosusC Gordon, G Bertsias, J P A Ioannidis, et al.
Lupus|February 14, 2009
European consensus statement on the terminology used in the management of lupus glomerulonephritisC Gordon, D Jayne, C Pusey, et al.
Lupus|February 23, 2011
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practiceM Mosca, M Govoni, P Tomietto, et al.
Annals of the Rheumatic Diseases|September 20, 2008
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patientsR Cervera, M A Khamashta, Y Shoenfeld, et al.
Annals of the Rheumatic Diseases|January 28, 2014
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsR Cervera, R Serrano, G J Pons-Estel, et al.
Genes and Immunity|October 21, 2011
The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosisJ-E Martin, F D Carmona, J C A Broen, et al.
Pageof 5